Abstract
Lipophilicity, often expressed as distribution coefficients (log D) in octanol/water, is an important physicochemical parameter influencing processes such as oral absorption, brain uptake and various pharmacokinetic (PK) properties. Increasing log D values increases oral absorption, plasma protein binding and volume of distribution. However, more lipophilic compounds also become more vulnerable to P450 metabolism, leading to higher clearance. Molecular size and hydrogen bonding capacity are two other properties often considered as important for membrane permeation and pharmacokinetics. Interrelationships among these physicochemical properties are discussed. Increasing size (molecular weight) often gives higher potency, but inevitably also leads to either higher lipophilicity, and hence poorer dissolution/solubility, or to more hydrogen bonding capacity, which limits oral absorption. Differences in optimal properties between gastrointestinal absorption and uptake into the brain are addressed. Special attention is given to the desired lipophilicity of CNS drugs. In examples using β-blockers, Ca channel antagonists and peptidic renin inhibitors we will demonstrate how potency and pharmacokinetic properties need to be balanced.
Similar content being viewed by others
References
Smith, D.A., Jones, B.C. and Walker, D.K., Med. Res. Rev., 16 (1996) 243-266.
Van de Waterbeemd, H., Carter, R.E., Grassy, G., Kubinyi, H., Martin, Y.C., Tute, M.S. and Willett, P., Pure Appl. Chem., 69 (1997) 1137-1152.
Pliska, V., Testa, B. and Van de Waterbeemd, H. (Eds.), Lipophilicity in Drug Action and Toxicology, VCH, Weinheim, 1996.
Smith, D.A., In Van de Waterbeemd, H., Testa, B. and Folkers, G. (Eds.), Computer-Assisted Lead Finding and Optimization, Wiley-VCH, Weinheim, 1997, pp. 267-276.
Wacher, V.J., Salphati, L. and Benet, L.Z., Adv. Drug Deliv. Rev., 20 (1996) 99-112.
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J., Adv. Drug Del. Res., 23 (1997) 3-25.
Yee, S.H., Pharm. Res., 14 (1997) 763-766.
Van de Waterbeemd, H., in Dressman, J. (Ed.), Methods for Assessing Oral Drug Absorption, Dekker, New York, NY 2000, pp. 31-49.
Camenisch, G., Alsenz, J., Van de Waterbeemd, H. and Folkers, G., Eur. J. Pharm. Sci., 6 (1998) 313-319.
Van de Waterbeemd, H., Eur. J. Pharm. Sci. 7 (1998) 1-3.
Van de Waterbeemd, H. and Kansy, M., Chimia, 46 (1992) 299-303.
Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G. and Artursson, P., J. Pharm. Sci., 85 (1996) 32-39.
Van de Waterbeemd, H., Camenisch, G., Folkers, G. and Raevsky, O.A., Quant. Struct. Act. Relat., 15 (1996) 480-490.
Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G., Beigi, F., Lundahl, P. and Artursson, P., J. Med. Chem., 41 (1998) 5382-5392.
Palm, K., Stenberg, P., Luthman, K. and Artursson, P., Pharm. Res., 14 (1997) 568-571.
Kansy, M., Senner, F. and Gubernator, K., J. Med. Chem., 41 (1998) 1007-1010.
Norinder, U., Österberg, T. and Artursson, P., Pharm. Res., 14 (1997) 1786-1791.
Winiwarter, S., Bonham, N.M., Ax, F., Hallberg, A. and Karlén, A., J. Med. Chem., 41 (1998) 4939-4949.
Gupta, S.P., Chem. Rev., 89 (1989) 1765-1800.
Van de Waterbeemd, H., Camenisch, G., Folkers, G., Chrétien, J.R. and Raevsky, O.A., J. Drug Target., 6 (1999) 151-165.
Fischer, H., Gottschlich, R. and Seelig, A., J. Membr. Biol., 165 (1998) 201-211.
Young, R.C., Mitchell, R.C., Brown, T.H., Ganellin, C.R., Griffith, R., Jones, M., Rana, K.K., Saunders, D., Smith, I.R., Sore, N.E. and Wilks, T.J., J. Med. Chem., 31 (1988) 656-671.
Lombardo, F., Blake, J.F. and Curatolo, W.J., J. Med. Chem., 39 (1996) 4750-4755.
Norinder, U., Sjöberg, P. and Österberg, T., J. Pharm. Sci., 87 (1998) 952-959.
Luco, J.M., J. Chem. Inf. Comput. Sci., 39 (1999) 396-404.
Rowley, M., Kulagowski, J.J., Watt, A.P., Rathbone, D., Stevenson, G.I., Carling, R.W., Baker, R., Marshall, G.R., Kemp, J.a., Foster, A.C., Grimwood, S., Hargreaves, R., Hurley, C., Saywell, K.L., Tricklebank, M.D. and Leeson, P.D., J. Med. Chem., 40 (1997) 4053-4068.
Van Asperen, J., Mayer, U., Van Tellingen, O. and Beijen, J.H., J. Pharm. Sci., 86 (1997) 881-884.
Yamada, Y., Ito, K., Nakamura, K., Sawada, Y. and Iga, T., Biol. Pharm. Bull., 16 (1993) 1251-1259.
Meir, J., Am. Heart J., 104 (1982) 364-373.
Hinderling, P.H., Schmidlin, O. and Seydel, J.K., J Bioharm Pharmacokinet., 2 (1984) 263-286.
Smith, D.A., Ackland, M.J. and Jones, B.C., Drug Disc. Today, 2 (1997) 406-414.
Smith, D.A., Ackland, M.J. and Jones, B.C., Drug Disc. Today, 2 (1997) 479-486.
Smith, D.A. and Jones, B., Drug Discov. Dev., 2 (1999) 33-41.
Ferrari, S., Leemann, T. and Dayer, P., Life Sci., 48 (1991) 2259-2265.
Spahn-Langguth, H., Baktir, G., Radschuweit, A., Okyar, A., Terhaag, B., Ader, P., Hanafy, A. and Langguth, P., Int. J. Clin. Pharm. Thev., 36 (1998) 16-24.
Hamilton, H.W., Steinbaugh, B.A., Stewart, B.H., Chan, O.H., Schmid, H.L., Schroeder, R., Ryan, M.J., Keiser, J., Taylor, M.D., Blankley, C.J., Kaltenbronn, J.S. Wright, J. and Hicks, J., J. Med. Chem., 38 (1995) 1446-1435.
Chan, O.H. and Stewart, B.H., Drug Discov. Today, 1 (1996) 461-473.
Rosenberg, S.H. and Kleinert, H.D., In Borchardt, R.T., Freidinger, R.M., Sawyer, T.K. and Smith, P.L. (Eds.) Integration of Pharmaceutical Discovery and Development. Case Histories, Plenum Press, New York, 1998, pp. 7-28.
Hilgert, M., Noldner, M., Chatterjee, S.S. and Klein, J. (1999) Neurosci. Lett., 263 (1999) 193-196.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van de Waterbeemd, H., Smith, D.A. & Jones, B.C. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 15, 273–286 (2001). https://doi.org/10.1023/A:1008192010023
Issue Date:
DOI: https://doi.org/10.1023/A:1008192010023